Estimation of Paracetamol in Urine to Assess the Diurnal Variation

NCT ID: NCT03122561

Last Updated: 2018-07-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-03

Study Completion Date

2018-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Paracetamol is an antipyretic drug that is taken orally at different times of the day in same dose. It is excreted mainly through renal route which may show diurnal variation. In this study, urinary excretion of paracetamol of 41 healthy men of same age group will be measured by HPLC after oral administration of 500 mg paracetamol tablet at morning, midday and night. The measured values will be compared in order to adjust doses of oral paracetamol at different times of the day.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Drug absorption, distribution, biotransformation and excretion are influenced by many different physiological functions of the body which may vary with time of the day. The time dependent changes in pharmacokinetics are due to circadian variation of human physiology and it is sometimes responsible for drug effects or adverse effects. Paracetamol is a widely used antipyretic and analgesic drug. It is usually well tolerated when used at the recommended dose. Paracetamol is a weak acidic drug that is rapidly absorbed and distributed after oral administration. It is metabolized extensively in liver and excrteted mainly through kidney as metabolites of paracetamol and some are as unchanged form. Paracetamol and its metabolites can be determined in biological fluids (urine, plasma, serum) by various mechanisms. High Performance Liquid Chromatography (HPLC) is a modern analytical chemistry technique by which paracetamol can be identified, separated and estimated from urine sample. This study is designed to investigate whether the excretion of paracetamol is changed or not if administered at same dose as oral tablet at three different times of the day. For this purpose after taking written informed consent 41 healthy men of aged 19- 23 will be provided 500 mg oral paracetamol tablet at morning, midday and night in two weeks interval and estimation of urinary paracetamol will be done by HPLC after paracetamol ingestion. A pilot study has been done and result shows highest concentration of paracetamol in urine after its oral administration found at 4th hour. Urine sample will be collected before and 4 hour after paracetamol administration in chloroform containing urine container and will be preserved in - 20 ̊C until analysis. Paracetamol standard has been collected from the same pharmaceutical company of which the drug will be used for study. Mobile phase will be consist of acetonitrile and distilled water and flow rate will be 0.5 ml/min at 25 ̊C temperature and 900 Psi pressure. The standard and sample will be analysed at a wavelength 254 nm. Total urinary paracetamol of that time will be estimated by multiplying total urinary volume in ml and concentration of paracetamol in one ml of urine. After measuring paracetamol at different times of the day, statistical analysis will be done to compare those values. If significant variation is found, adjustment of dose of oral paracetamol in different time of the day will be tried.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diurnal Variation of Paracetamol Excretion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Healthy Volunteers
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Paracetamol 500 mg tablet at Morning

Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at morning

Group Type OTHER

Paracetamol 500 mg tablet at morning

Intervention Type DRUG

Single dose oral paracetamol will be administered at 8.00 am

Paracetamol 500 mg tablet at Midday

Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at midday

Group Type OTHER

Paracetamol 500 mg tablet at midday

Intervention Type DRUG

Single dose oral paracetamol will be administered at 2.00 pm

Paracetamol 500 mg tablet at Night

Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at night

Group Type OTHER

Paracetamol 500 mg tablet at night

Intervention Type DRUG

Single dose oral paracetamol will be administered at 8.00 pm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Paracetamol 500 mg tablet at morning

Single dose oral paracetamol will be administered at 8.00 am

Intervention Type DRUG

Paracetamol 500 mg tablet at midday

Single dose oral paracetamol will be administered at 2.00 pm

Intervention Type DRUG

Paracetamol 500 mg tablet at night

Single dose oral paracetamol will be administered at 8.00 pm

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tablet. Ace Tablet. Ace Tablet. Ace

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The healthy male student volunteers of Eastern Medical College having age range between 19 and 23 years

Exclusion Criteria

* Age \<19 years , \>23 years
* Volunteers on analgesic or antipyretic medication
* Volunteers with history of hypersensitivity to paracetamol
* Volunteers taking any enzyme inducing or enzyme inhibiting drug
* Volunteers with impaired renal or hepatic function
Minimum Eligible Age

19 Years

Maximum Eligible Age

23 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof. Mir Misbahuddin

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mir Misbahuddin, PhD

Role: STUDY_DIRECTOR

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Eastern Medical College

Comilla, , Bangladesh

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Bangladesh

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BSMMU-013-CT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Paracetamol for Cancer Pain
NCT01313247 UNKNOWN PHASE4
Paracetamol for Intrapartum Analgesia
NCT02578251 UNKNOWN PHASE2
4-methylpyrazole and Acetaminophen Metabolism
NCT03878693 COMPLETED EARLY_PHASE1